PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood.
PATH EX has raised $5.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in May 2025.
PATH EX's investors include National Science Foundation, MassChallenge, Fitz Gate Ventures, Innova Memphis, IAG Capital Partners.
PATH EX is headquartered in Nashville, United States.
PATH EX has developed a proprietary technology to selectively separate and capture bacteria and toxins from human blood.
PATH EX is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"PATH EX — Funding & Investors." VCBacked, May 8, 2025, https://www.vcbacked.co/company/path-ex. Accessed July 19, 2026.
VCBacked. (2025). PATH EX — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/path-ex
{{cite web |title=PATH EX — Funding & Investors |url=https://www.vcbacked.co/company/path-ex |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated